Regular use of pain relievers over many years may increase the risk of hearing loss, a recent study suggests.
It’s expected that a large number of clinical trials will result in failure. 2016 saw numerous trial failures, but analysts at The Motley Fool selected seven failures that are expected to have a direct impact on the forward outlooks of the companies involved.
Roche Holding AG’s emicizumab drug for treating hemophilia A showed it worked in a phase III study, the Swiss drugmaker said.
Merrimack Pharmaceuticals will stop a study for advanced breast cancer after an analysis suggested its drug would unlikely show superiority over chemo.
Ionis Pharmaceuticals Inc. said its rare metabolic disorder drug for severe hypertriglyceridemia met the main goal in a late-stage study.
Proteon Therapeutics Inc. said its experimental chronic kidney disease drug failed to meet the main goal in a late-stage study.
A recent study published in Nature suggests there exists a biological barrier on human life expectancy that effectively can not be broken.
Achaogen Inc.’s plazomicin – being developed to fight multi-drug resistant bacterial infections – was successful in two pivotal studies.
Novartis announced combining Lucentis with Fovista in patients with nAMD did not produce better outcomes than treatment with Lucentis alone.
A scalp-cooling system helped prevent hair loss in women with breast cancer undergoing chemo, researchers said at the San Antonio Breast Cancer Symposium.